06.13.25 -- The Hidden Risk In Cell & Gene Therapy Commercialization

Bringing potentially curative cell and gene therapies to more patients requires a focused approach to market access. Discover essential insights into payer dynamics and treatment evolution.

The willingness to seek expert support from Rescue CROs when clinical trials face critical challenges is not a sign of weakness but a demonstration of accountability and commitment to excellence.

Bladder cancer ranks ninth in incidence and 13th in mortality among cancers. Recent advancements in treatment are transforming the management of advanced bladder cancer cases.

Real-world evidence (RWE) is transforming clinical trials by enabling the use of external control arms (ECAs), which serve as an alternative to traditional randomized control groups.

Explore the findings of a survey of 124 U.S. oncologists focused on better understanding the current use of cell and gene therapies (CGTs) and possible barriers to future adoption.

In order to advance viral vectors like AAVs, there's a growing need for technologies and platforms that facilitate reliable and safe handling all the way from production to shipping and storage.

Explore how to develop a strong packaging system, and learn more about why a reliable supply chain is critical for drug substance and drug product transport.